目的 观察参脉注射液联合左卡尼汀治疗急性冠脉综合征心律失常的临床疗效。方法 选取2015年1月-2017年5月如皋市人民医院收治的急性冠脉综合征继发室性心律失常患者90例，随机分为对照组和治疗组，每组各45例。对照组静脉滴注左卡尼汀注射液，3 g/次，1次/d；治疗组在对照组的基础上静脉滴注参麦注射液，2 mL/次，1次/d。两组患者均连续治疗2周。评价两组患者临床疗效，同时比较治疗前后两组患者心电图检测结果和血清指标水平。结果 治疗后，对照组和治疗组临床有效率分别为68.89%和93.33%，两组比较差异有统计学意义（P<0.05）。治疗后，两组室早数、短阵室速较治疗前显著减少，QTc间期显著延长，同组比较差异具有统计学意义（P<0.05）；且治疗组室早数、短阵室速明显少于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组血清CD40配体（CD40L）、白介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）水平均较治疗前显著降低（P<0.05）；且治疗后治疗组CD40L、IL-1β和TNF-α水平显著低于对照组（P<0.05）。结论 参脉注射液联合左卡尼汀治疗急性冠脉综合征室性心律失常临床疗效显著，可有效地降低炎症细胞因子水平，具有一定的临床推广应用价值。

Objective To observe the clinical curative effect of Shenmai Injection combined with levocarnitine in treatment of ventricular arrhythmia of acute coronary syndrome. Methods Patients (90 cases) with ventricular arrhythmia of acute coronary syndrome in Rugao People's Hospital from January 2015 to May 2017 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were iv administered with Levocarnitine Injection, 3 g/time, once daily. Patients in the treatment group were iv administered with Shenmai Injection on the basis of the control group, 2 mL/time, once daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, the ECG results and the serum index levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 68.89% and 93.33% respectively, and there were differences between two groups (P<0.05). After treatment, the ventricular arrhythmias and nonsustained ventricular tachycardia in two groups were significantly decreased, and QTc interval was significantly prolonged, and the difference was statistically significant in the same group (P<0.05). And the ventricular arrhythmias and nonsustained ventricular tachycardia in the treatment group after treatment were significantly less than those in the control group, with significant difference between two groups (P<0.05). After treatment, the serum CD40L, IL-1β, and TNF-α levels in two groups were significantly decreased (P<0.05), and these serum indexes levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). Conclusion Shenmai Injection combined with levocarnitine has good effect in treatment of ventricular arrhythmia of acute coronary syndrome, and can decrease inflammatory cytokine levels, which has a certain clinical application value.